EUCTR2011-005659-15-IT进行中（未招募）1 期
A phase 2a, open-label, dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta(ß)-thalassemia - ACE-011-B-THAL-001
CELGENE CORPORATIO0 个研究点目标入组 46 人开始时间: 2012年10月25日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 46
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Men and women = 18 years of age at the time of signing the informed consent document with a diagnosis of ß-thalassemia major(including all subtypes)or ß-thalassemia intermedia.
- •2.For transfusion dependent subjects: permanent transfusion dependency is defined as requiring packed red blood cells(pRBCs)and iron chelation therapy:
- •Average transfusion requirement of at least 2 units/30 days of pRBCs(Gale, 2011)confirmed for a minimum of 168 days(six months)immediately preceding enrollment(study Day 1);
- •No transfusion-free period of more than 45 consecutive days during the 168 days immediately preceding enrollment;
- •Prior transfusion hemoglobin levels = 10.5 g/dL.
- •3.For non-transfusion dependent subjects: non-transfusion dependency is defined as a transfusion free for a minimum of 168 days immediately preceding enrollment,with the exception of = to one episode of transfusion in the period of a minimum of 168 days immediately preceding enrollment(One episode of transfusion is defined as = 4 transfusion units administered,occurred within 42 days [first transfusion is counted as day 1] due to concurrent illness[e.g. infection],[Guidelines Clin Management of Thalassaemia, 2008]).
- •4.Performance status: ECOG score of 0 to 1
- •5.No concurrent severe hepatic disease:
- •AST or ALT no greater than 3 x upper limit of normal (ULN);
- •Albumin = 3 g/dL.
- •6.Serum creatinine = 1.5 x ULN.
- •7.Females of childbearing potential participating in the study are to use highly effective methods of birth control during study participation and for 112 days (approximately five times the mean terminal half-life of sotatercept [23 days] based on multiple-dose PK data) following the last dose of sotatercept. FCBP must have a negative serum beta human chorionic gonadotropin (ß-HCG) pregnancy test within three days of sotatercept dosing (Day 1). Subjects must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sotatercept. A FCBP is a sexually mature woman who has not undergone a hysterectomy or bilateral oophorectomy or who has not been postmenopausal for at least 24 consecutive months (i.e.,who has had menses at some time in the preceding 24 months).
- •8.Males must agree to use a latex condom during any sexual contact with FCBSs while participating in the study and for 112 days following the last dose of sotatercept, even if he has undergone a successful vasectomy. Subjects must be counseled concerning measures to be used to prevent pregnancy and potential toxicities prior to the first dose of sotatercept.
- •9.Agreement to adhere to the study visit schedule, understand and comply with all protocol requirements.
- •10.Understand and provide written informed consent.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range: 0
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 25
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 5
排除标准
- •1.Any serious medical condition, laboratory abnormality, or psychiatric illness that would prevent the subject from signing participating in the study.
- •2.Evidence of active hepatitis C antibody (HCV), hepatitis B surface antigen (HBsAg and HB core Ab), or human immunodeficiency virus (HIV) antibody.
- •3.Known history of thromboembolic events = Grade 3 according to NCI CTCAE version 4.0 (current active minor version).
- •4.Subjects with insulin dependent diabetes.
- •5.Subjects with major cardiac problems such as:
- •Major risk of heart failure, confirmed with myocardiac T2* = 10 ms. Myocardiac T2* performed in the last one and a half years prior to subject enrollment will be considered valid.
- •Cardiac arrhythmia which requires treatment (i.e atrial fibrillation).
- •6.Treatment with another investigational drug or device < 28 days prior to study entry.
- •7.Use of an erythropoiesis stimulating agent (ESA) within the 28 days prior to enrollment (study Day 1).
- •8. Subjects on hydroxyria treatment for which the dose was changed in the last one year prior to subject enrollment.
- •9. Subjects on anticoagulant therapy, such as warfarin.
- •10.Subjects who started bisphosphonates within the last three months prior to subject enrollment.
- •11.Pregnant or lactating females.
- •12. Uncontrolled hypertension. Controlled hypertension for this protocol is considered = Grade 1 according to NCI CTCAE version 4.0 (current active minor version)
- •13. A history of major organ damage including:
- •Liver disease with ALT > 3x ULN or histopathological evidence of liver cirrhosis on liver biopsy;
- •Heart disease with ejection fraction = Grade 2 according to NCI CTCAE version 4.0 (current active minor version);
- •Kidney disease with a calculated creatinine clearance < 40 mL/min (Cockcroft-Gault formula);
- •Pulmonary fibrosis or pulmonary hypertension as confirmed by a specialist.
- •14. Adrenal insufficiency.
- •15. Heart failure as classified by the New York Heart Association (NYHA) classification of 3 or higher.
- •16. Major surgery within 30 days prior to study Day 1 (subjects must have completely recovered from any previous surgery prior to study Day 1).
- •17. History of severe allergic or anaphylactic reactions or hypersensitivity to recombinant proteins or excipients in the investigational product (see Investigator Brochure).
研究者
相似试验
进行中（未招募）
1 期
Dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia (ß-thalassemia)Subjects with red blood cell (RBC) transfusion dependent ß-thalassemia major and ß thalassemia intermedia, as well as non-transfusion dependent ß-thalassemia intermedia will take part in this study.MedDRA version: 20.1Level: LLTClassification code 10062923Term: Thalassemia intermediaSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10054661Term: Thalassemia majorSystem Organ Class: 100000004850MedDRA version: 20.1Level: LLTClassification code 10054660Term: Thalassemia betaSystem Organ Class: 100000004850EUCTR2011-005659-15-GRCelgene Corporation85
进行中（未招募）
1 期
Dose finding study to determine the safety and tolerability of sotatercept (ACE-011) in adults with beta-thalassemia (ß-thalassemia)EUCTR2011-005659-15-GBCelgene Corporation85
进行中（未招募）
1 期
Open-label, ascending-dose, Phase II study to determine the minimum effective dose of APD421 (intravenous amisulpride) in the prevention of cisplatin-induced nausea and vomiting - Phase II proof-of-concept study of APD421Cisplatin-induced nausea and vomitingMedDRA version: 13Level: LLTClassification code 10054133Term: Prophylaxis of nausea and vomitingEUCTR2010-022170-14-DKAcacia Pharma Ltd54
进行中（未招募）
不适用
Open-label, ascending-dose, Phase II study to determine the minimum effective dose of APD421 (intravenous amisulpride) in the prevention of cisplatin-induced nausea and vomiting - Phase II proof-of-concept study of APD421EUCTR2010-022170-14-GBAcacia Pharma Ltd40
进行中（未招募）
不适用
A phase 2 randomized, controlled, open-label dose-blinded , multi-center, dose-finding study of the safety and efficacy of I-0401 in the treatment of patients with fractures of the tibial plateau requiring grafting. - NDEUCTR2006-003688-30-ITKUROS BIOSURGERY AG180